OBJECTIVES:  To assess, from the payer perspective, the cost and consequences of RTS-Baxter´s Renal Disease Management Model (DMM) for patients in dialysis, that is currently implemented in a Colombian Payer since 2013. METHODS:  A one year Markov model, applying a three stages structure, was used to project ambulatory care, hospitalizations and deaths from 2.500 dialysis patients with and without DMM. Hospitalization and death rates were obtained from retrospective real world patient level data from RTS-Baxter registries. Ambulatory costs were estimated from referent dialysis tariffs. Inpatient care costs were collected from administrative database in a referent health care provider. Outcomes included: direct costs, events of hospitalizations, days in hospitalization and deaths. Both deterministic and probabilistic sensitivity analyses were done. RESULTS: Base case results for 2,500 cohort with DMM: Total cost COP 96,759,074,327; Inpatient care cost COP 24,804,142,382; Hospitalizations 2,572; Days of hospitalization 21,550; deaths 302. Base case results for 2,500 cohort without DMM: Total cost COP 98,266,101,230; Inpatient care cost COP 29,549,539,186; Hospitalizations 3,076; Days of hospitalization 24,453; deaths 332. Deterministic analysis: Dialysis tariff, hospitalization rate and hospitalization costs are sensitive parameters. Probabilistic analysis: The DMM is dominant in 60% of the simulations. CONCLUSIONS:  DMM is a cost saving alternative from the perspective of the analyzed payer, improving hospitalization outcomes and mortality.